New opportunities of evaluation of ischemic stroke secondary prophylaxis effectiveness in therapeutic practice

Aim. Study of antibodies to NR2-subunit of NMDA receptor level dynamics in patients after first ischemic stroke (IS) after use of Mildronate® 1000 mg per day. Materials and methods. The study included 45 patients (25 male, 20 female) aged 45 to 83 years at the time of first IS development. The patients were randomized into 2 groups: group 1 patients (n=30) received Mildronate® in capsules 500 mg twice a day for 45 days combined with neurorehabilitation complex; group 2 patients (n=15) did not receive Mildronate®. Evaluation of antibodies to NR2 protein was performed twice (at the beginning of therapy and at the end of therapy) in all study patients with the use of Gold Dot Test (CIS Biotech, Inc., Atlanta, GA) blood test. Results. A significant decrease of concentration of central nervous system (CNS) ischemia marker - antibodies to NR2-subunit of NMDA receptor was observed in the group of patients who received Mildronate® 1000 mg per day for 45 days. Conclusions. According to acquired data it may be concluded that inclusion of Mildronate® 1000 mg per day for 45 days in neurorehabilitation period therapy results in significant decrease of CNS ischemia marker - antibodies to NR2-subunit of NMDA receptor concentration that may indicate decrease of ischemic CNS injury.

ischemic stroke, Mildronate, antibodies to NR2-subunit of NMDA receptor